Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption

Alejandro Orlowski, Thomas Weber

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


One of the greatest barriers for the use of adeno-associated vectors (AAV) in gene therapy is the presence of pre-existing antibodies against AAV in the general population. Since many of the anti-AAV antibodies have the ability to neutralize the transduction target tissues, even patients with low antibody titers must be excluded from clinical trials or therapy. In recent years, various methods have been proposed to overcome this problem, unfortunately with limited success. In this chapter, we describe in detail a protocol for hemapheresis with an immunoadsorption matrix to remove specifically anti-AAV antibodies in an in vivo rat model. Furthermore, this chapter describes in detail the methods to determine the efficiency of hemapheresis and immunoadsorption.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Number of pages14
StatePublished - 2022

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029


  • Adeno-associated virus
  • Hemapheresis
  • Immunoadsorption
  • Neutralization assay
  • Neutralizing antibodies
  • Plasmapheresis


Dive into the research topics of 'Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption'. Together they form a unique fingerprint.

Cite this